165,429 Shares in Astera Labs, Inc. $ALAB Bought by Ossiam

Ossiam purchased a new position in Astera Labs, Inc. (NASDAQ:ALABFree Report) in the third quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The firm purchased 165,429 shares of the company’s stock, valued at approximately $32,391,000. Ossiam owned 0.10% of Astera Labs at the end of the most recent quarter.

Several other hedge funds and other institutional investors have also recently bought and sold shares of the stock. Vanguard Group Inc. boosted its position in shares of Astera Labs by 29.6% during the 2nd quarter. Vanguard Group Inc. now owns 12,049,223 shares of the company’s stock worth $1,089,491,000 after purchasing an additional 2,751,747 shares in the last quarter. Rafferty Asset Management LLC bought a new stake in Astera Labs in the 3rd quarter valued at about $209,599,000. BNP Paribas Financial Markets increased its position in Astera Labs by 577.3% in the 3rd quarter. BNP Paribas Financial Markets now owns 1,127,340 shares of the company’s stock valued at $220,733,000 after buying an additional 960,899 shares in the last quarter. 1832 Asset Management L.P. raised its stake in Astera Labs by 151.4% during the 2nd quarter. 1832 Asset Management L.P. now owns 1,543,500 shares of the company’s stock worth $139,563,000 after buying an additional 929,600 shares during the period. Finally, Holocene Advisors LP acquired a new position in Astera Labs during the 2nd quarter worth approximately $55,827,000. 60.47% of the stock is owned by institutional investors.

Insiders Place Their Bets

In related news, COO Sanjay Gajendra sold 94,971 shares of the company’s stock in a transaction that occurred on Tuesday, February 17th. The stock was sold at an average price of $123.81, for a total value of $11,758,359.51. Following the transaction, the chief operating officer owned 1,531,301 shares in the company, valued at approximately $189,590,376.81. This represents a 5.84% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this link. Also, General Counsel Philip Mazzara sold 10,000 shares of the stock in a transaction on Monday, March 2nd. The shares were sold at an average price of $117.47, for a total value of $1,174,700.00. Following the transaction, the general counsel directly owned 128,084 shares of the company’s stock, valued at approximately $15,046,027.48. This trade represents a 7.24% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. Insiders have sold 224,292 shares of company stock valued at $27,676,069 in the last quarter. 12.50% of the stock is currently owned by company insiders.

Analysts Set New Price Targets

A number of equities research analysts have commented on the company. Royal Bank Of Canada started coverage on Astera Labs in a research note on Wednesday, January 14th. They issued an “outperform” rating and a $225.00 price objective for the company. Morgan Stanley reaffirmed an “overweight” rating and set a $210.00 target price on shares of Astera Labs in a research report on Wednesday, December 3rd. Raymond James Financial began coverage on Astera Labs in a report on Friday, November 21st. They issued a “hold” rating on the stock. Citigroup reduced their price target on shares of Astera Labs from $275.00 to $250.00 and set a “buy” rating for the company in a research report on Wednesday, February 11th. Finally, Jefferies Financial Group restated a “buy” rating on shares of Astera Labs in a research note on Wednesday, December 3rd. Fifteen investment analysts have rated the stock with a Buy rating, six have assigned a Hold rating and one has issued a Sell rating to the company’s stock. Based on data from MarketBeat.com, the stock presently has an average rating of “Moderate Buy” and an average price target of $202.22.

View Our Latest Report on Astera Labs

Astera Labs Stock Performance

NASDAQ:ALAB opened at $120.31 on Friday. Astera Labs, Inc. has a 52 week low of $47.13 and a 52 week high of $262.90. The firm has a 50-day moving average price of $147.89 and a two-hundred day moving average price of $168.18. The firm has a market cap of $20.48 billion, a price-to-earnings ratio of 98.61, a price-to-earnings-growth ratio of 2.36 and a beta of 1.74.

Astera Labs (NASDAQ:ALABGet Free Report) last announced its earnings results on Tuesday, February 10th. The company reported $0.58 earnings per share for the quarter, topping analysts’ consensus estimates of $0.51 by $0.07. Astera Labs had a return on equity of 16.12% and a net margin of 25.70%.The firm had revenue of $270.58 million for the quarter, compared to the consensus estimate of $249.46 million. During the same quarter in the previous year, the business earned $0.37 EPS. The company’s revenue was up 91.8% compared to the same quarter last year. Astera Labs has set its Q1 2026 guidance at 0.530-0.540 EPS. As a group, sell-side analysts forecast that Astera Labs, Inc. will post 0.34 earnings per share for the current year.

Astera Labs Profile

(Free Report)

Astera Labs is a fabless semiconductor company that develops connectivity solutions for data center and cloud infrastructure. The firm focuses on addressing signal integrity and link management challenges that arise as server architectures incorporate higher-bandwidth processors and accelerators. Its technology is aimed at improving reliability and performance for high-speed interconnects used in servers, storage systems and compute accelerators.

The company’s product portfolio centers on silicon devices and accompanying firmware and software that enhance and manage high-speed links.

Featured Stories

Institutional Ownership by Quarter for Astera Labs (NASDAQ:ALAB)

Receive News & Ratings for Astera Labs Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Astera Labs and related companies with MarketBeat.com's FREE daily email newsletter.